Literature DB >> 15583315

Surface immunoglobulin-deficient Epstein-Barr virus-infected B cells in the peripheral blood of pediatric solid-organ transplant recipients.

Elizabeth Schauer1, Steven Webber, Michael Green, David Rowe.   

Abstract

Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, normally causes an asymptomatic latent infection with very low levels of circulating virus in the peripheral blood of infected individuals. However, EBV does have pathogenic potential and has been linked to several diseases, including posttransplant lymphoproliferative disease (PTLD), which involves very high circulating viral loads. As a consequence of immunosuppression associated with transplantation, children in particular are at risk for PTLD. Even in the absence of symptoms of PTLD, very high viral loads are often observed in these patients. EBV-infected B cells in the circulations of 16 asymptomatic pediatric solid-organ transplant recipients from Children's Hospital of Pittsburgh were simultaneously characterized for their surface immunoglobulin (sIg) isotypes and EBV genome copy numbers. Patients were characterized as having high and low viral loads on the basis of their stable levels of circulating virus. Patients with high viral loads had both high- and low-copy-number cells. Cells with a high numbers of viral episomes (>20/cell) were predominantly Ig null, and cells with low numbers of episomes were predominantly sIgM positive. Patients with low viral loads carried the vast majority of their viral load in low-copy-number cells, which were predominantly IgM positive. The very rare high-copy-number cells detected in carriers with low viral loads were also predominantly Ig-null cells. This suggests that two distinct types of B-lineage cells contribute to the viral load in transplant recipients, with cells bearing high genome copy numbers having an aberrant Ig-null cellular phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583315      PMCID: PMC535249          DOI: 10.1128/JCM.42.12.5802-5810.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Post-transplantation lymphoproliferative disorders: advances in diagnosis, prevention and management in children.

Authors: 
Journal:  Prog Pediatr Cardiol       Date:  2000-06-01

2.  Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease.

Authors:  P Vajro; S Lucariello; F Migliaro; E Sokal; B Gridelli; A Vegnente; R Iorio; F Smets; I Quinto; G Scala
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

3.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.

Authors:  M Rowe; G Niedobitek; L S Young
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

Authors:  J Yang; Q Tao; I W Flinn; P G Murray; L E Post; H Ma; S Piantadosi; M A Caligiuri; R F Ambinder
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

6.  Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.

Authors:  M L Mihalov; P Gattuso; K Abraham; E W Holmes; V Reddy
Journal:  Clin Transplant       Date:  1996-06       Impact factor: 2.863

7.  Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease.

Authors:  M Green; T V Cacciarelli; G V Mazariegos; L Sigurdsson; L Qu; D T Rowe; J Reyes
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

8.  Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.

Authors:  S D Zangwill; D T Hsu; M R Kichuk; J H Garvin; C J Stolar; J Haddad; S Stylianos; R E Michler; A Chadburn; D M Knowles; L J Addonizio
Journal:  J Heart Lung Transplant       Date:  1998-12       Impact factor: 10.247

9.  Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization.

Authors:  Camille Rose; Michael Green; Steven Webber; Lawrence Kingsley; Roger Day; Simon Watkins; Jorges Reyes; David Rowe
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

10.  A novel form of Epstein-Barr virus latency in normal B cells in vivo.

Authors:  E M Miyashita; B Yang; K M Lam; D H Crawford; D A Thorley-Lawson
Journal:  Cell       Date:  1995-02-24       Impact factor: 41.582

View more
  4 in total

Review 1.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function.

Authors:  Camila Macedo; Steven A Webber; Albert D Donnenberg; Iulia Popescu; Yun Hua; Michael Green; David Rowe; Louise Smith; Maria M Brooks; Diana Metes
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

3.  Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH.

Authors:  Sara Calattini; Irini Sereti; Philip Scheinberg; Hiroshi Kimura; Richard W Childs; Jeffrey I Cohen
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

Review 4.  Laboratory assays for Epstein-Barr virus-related disease.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.